Features  |   May 2018
Sugammadex: A New Reversal Drug With the Same Risk - A Continued Need for Neuromuscular Blockade Monitoring
Author Affiliations
  • David Dunipace, CAA, M.S.
    Committee on Patient Safety and Education
  • Jamie L. Sparling, M.D.
    Committee on Patient Safety and Education
Article Information
Neuromuscular Diseases and Drugs / Neurosurgical Anesthesia / Features
Features   |   May 2018
Sugammadex: A New Reversal Drug With the Same Risk - A Continued Need for Neuromuscular Blockade Monitoring
ASA Monitor 5 2018, Vol.82, 32-34.
ASA Monitor 5 2018, Vol.82, 32-34.
Many studies continue to suggest an inconsistent use of neuromuscular blockade (NMB) monitoring by anesthesia providers resulting in patient harm from residual paralysis. In order to better understand this problem, as part of a patient safety initiative, the Anesthesia Patient Safety Foundation (APSF) surveyed anesthesia professionals and PACU nurses on their practices and perceptions of neuromuscular blockade, monitoring and reversal (Table 1).
In the survey, several questions were asked about the practices and perceptions pertaining to the reversal drug sugammadex. Specifically, the anesthesia providers were asked:
A significant percentage of the anesthesia providers indicated a response of “monitoring not needed” or “do not know if monitoring is needed” when sugammadex is administered for reversal (Figure 1).
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×